Live Breaking News & Updates on Medac Pharma Inc|Page 1

Stay updated with breaking news from Medac pharma inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021
Medexus Pharmaceuticals IncMarch 1, 2021 GMT
TORONTO, CHICAGO and MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced its financial and operating results for the three and nine months ended December 31, 2020. All dollar amounts below are in Canadian dollars unless specified otherwise.
Third Quarter Fiscal 2021 Financial Highlights:
The Company achieved record revenue of $31.5 million for the three-month period ended December 31, 2020, versus $16.2 million for the same period last year. As previously reported, the revenue for the period included approximately $3 million in IXINITY® revenues, which were originally expected to be realized in September 2020, but were i ....

United States , Tina Byers , Roland Boivin , Aptevo Therapeutics Inc , Company Nasdaq , Aptevo Biotherapeutics , Medexus Pharmaceuticals , Company On , Medac Pharma Inc , Venture Exchange , Regulation Services Provider , Medexus Pharma Inc , Stifel Nicolaus Canada Inc , Crescendo Communications , Medexus Inc , Health Canada Special Access Program , Medexus Pharmaceuticals Inc , Company Investor Events , Raymond James Ltd , Health Canada , Customer Service , Quarter Fiscal , Adjusted Net , Chief Executive Officer , North American , Deal Public Offering ,

Medexus Announces Closing of $32.5 Million Public Offering, Including Exercise in Full of Over-Allotment Option


NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
TORONTO, CHICAGO and MONTREAL, Feb. 23, 2021 (GLOBE NEWSWIRE) Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (Frankfurt: P731) announced today that it has closed its previously announced bought deal public offering of 4,581,689 units (the “Units”) at a price of $7.10 per Unit for total gross proceeds of approximately $32,529,992 (the “Offering”), including 597,611 Units sold pursuant to the exercise in full of the over-allotment option granted to the Underwriters (as defined herein).
The Offering was led by Raymond James Ltd. and Stifel GMP, as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters consisting of Roth Canada, ULC, Bloom Burton Securities Inc. and Mackie Research Capital Corporation (collectively, the “Underwriters”). ....

United States , South Australia , Tina Byers , Roland Boivin , Crescendo Communications , Medexus Inc , Bloom Burton Securities Inc , Mackie Research Capital Corporation , Medexus Pharmaceuticals , Medexus Pharmaceuticals Inc , Raymond James Ltd , Medac Pharma Inc , Venture Exchange , Customer Service , Raymond James , Roth Canada , Bloom Burton Securities , Common Share , Each Warrant , Common Shares , United States Securities Act , North American , Chief Executive , Chief Financial , Medac Pharma , ஒன்றுபட்டது மாநிலங்களில் ,